Searchable abstracts of presentations at key conferences in endocrinology

ea0090p29 | Calcium and Bone | ECE2023

TransCon PTH Improves Health-Related Quality of Life and Reduces Work Limitations in Adults With Hypoparathyroidism: Patient-Reported Outcomes in the Phase 3 PaTHway Trial

Palermo Andrea , Khan Aliya , Rubin Mishaela , Schwarz Peter , Shoback Dolores M. , Gagnon Claudia , Cetani Filomena , Clarke Bart L. , Tsourdi Elena , Kohlmeier Lynn , Sikjaer Tanja , M Kaiser Stephanie , Lai Bryant , Le John , Ukena Jenny , Sibley Christopher , Shu Aimee , An Xubei , Noori Wahidullah , Smith Alden , Vokes Tamara J.

Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...

ea0070aep180 | Bone and Calcium | ECE2020

Baseline characteristics from the observational paradighm registry of patients with chronic hypoparathyroidism

L Clarke Bart , Rejnmark Lars , Ing Steven , Luisa Brandi Maria , Björnsdottir Sigridur , Hahner Stefanie , Hofbauer Lorenz C , Houillier Pascal , Khan Aliya A , Levine Michael A , Mannstadt Michael , M Shoback Dolores , Vokes Tamara J , Zhang Pinggao , Marelli Claudio , Germak John , Gittoes Neil

PARADIGHM is an actively recruiting, prospective, observational registry (NCT01922440/EUPAS16927). The primary objective is to evaluate the safety and effectiveness of recombinant human parathyroid hormone, rhPTH(1-84), treatment in patients with chronic hypoparathyroidism under routine clinical care. The secondary objective is tocharacterize the clinical course of chronic hypoparathyroidism under conditions of routine clinical practice. At enrollment, registry inclusion crite...

ea0057031 | TSH receptor-blocking autoantibodies: the pregnancy paradigm | BES2018

TSH receptor-blocking autoantibodies: the pregnancy paradigm

Martens P-J , Polders C , Decallonne B

Background: GravesÂ’ disease (GD) is an autoimmune disease caused by antibodies directed to the TSH receptor (TRAb), which can be activating (TSAb), neutral, or blocking (TBAb). This balance determines the final clinical result. Typically TSAbs dominate, resulting in hyperthyroidism. Rarely, TBAbs prevail and result in hypothyroidism (1). The TRAb assay routinely used in the clinic does not allow to differentiate between stimulating or blocking characteristics.<p class...

ea0003p281 | Thyroid | BES2002

Delayed resolution of endothelial dysfunction despite biochemical correction of thyrotoxicosis

Obuobie K , Evans S , Lazarus J

Endothelial dysfunction contributes to the cardiovascular complications in Diabetes mellitus and hypertension. The effects of hyperthyroidism on the peripheral vasculature are not fully understood. Decreased central arterial stiffness is a feature of thyrotoxicosis and normalises with treatment (1). The purpose of our study was to establish the effect of thyrotoxicosis and its treatment on surrogate humoral markers of endothelial function; Von Willebrand factor (VWF), Soluble ...

ea0006oc4 | Young Endocrinologist Session | SFE2003

Influence of Annexin 1 gene deletion on dopaminergic cell numbers in the mid-brain

Shah A , McArthur S , Morris J , Flower R , Buckingham J , Gillies G

There is now substantial evidence to suggest that the early life environment can have a permanent effect on adult physiology. Recently we have shown that early postnatal glucocorticoid (GC) exposure produces alterations in midbrain dopaminergic cell number in the adult rat, in a gender-specific manner (McArthur et al., Brit. Neurosci. Assoc. Abstr. 2003;17:27). Since the protein annexin 1 (ANXA1) mediates some aspects of the effects of GCs within the immune system and the hypo...

ea0081ep186 | Calcium and Bone | ECE2022

Bone tissue metabolism in children with dystrophic form of congenital epidermolysis bullosa before and during therapy with cholecalciferol.

Pronina Irina , Makarova Svetlana , Murashkin Nikolay , Semikina Elena , Chumbadze Tamara

Introduction: Malnutrition, deficiency of micro- and macronutrients, including calcium and vitamin D are typical for children with dystrophic form of congenital epidermolysis bullosa (DEB). Thereby, there is a slowdown in osteogenesis and in stimulation of osteoclast activity, bone tissue resorption, which leads to increased bone fragility and low-traumatic fractures.Aim of the study: To evaluate markers of bone tissue metabolism and phosphorus-calcium m...

ea0081ep218 | Calcium and Bone | ECE2022

Results of denosumab used in postmenopausal women

Navmenova Yana , Makhlina Elena , Moskvicheva Tamara , Chernova Nelli , Savasteeva Irina

The aim of the study was to assess the effectiveness of postmenopausal osteoporosis (PMOP) therapy with denosumab.Patients and methods 32 postmenopausal women with established PMOP for a period of 24 months or more received denosumab 60 mg subcutaneously once every 6 months combined with calcium and vitamin D. A quantitative assessment of bone mineral density (BMD) was carried out before treatment, after 12 and 24 months of observation, using dual-energy X-ray absorptiometry o...

ea0090ep1163 | Late Breaking | ECE2023

The Association of Immunotherapy-Related Thyroid Disorders and Mortality in Patients with RCC and Melanomas

Ehrenwald Michal , Kolitz Tamara , Karov Ruth , Brenner Ronen , Greenman Yona

Background: Immune checkpoint inhibitors (ICPIs) are indicated as treatment for metastatic renal cell carcinoma (RCC) and melanoma, among other malignancies. This group of agents is associated with immune-related adverse events (irAEs). We aimed to further investigate the association of immune-related thyroid disorders (irTDs) with clinical outcomes and mortality rates in patients with RCC or melanoma who were treated with ICPIs.Methods: We retrospective...

ea0063p143 | Diabetes, Obesity and Metabolism 1 | ECE2019

Clinical importance of determination of glytoxic methylglyoxal in nafld and type 2 type

Larisa Zvenigorodskaya , Michael Shinkin , Alexander Petrakov , Tamara Nilova

Introduction: The formation of oxidative stress in the biological reaction of inflammation is accompanied by the formation of methylglyoxal (MG), which initiates the glycosylation reaction of proteins. When hyperglycemia MG content significantly increased. MG interacts with the amino groups of lysine and arginine to form further glycation end products (CNG). Glycation is due to the ability of glucose to form irreversible chemical compounds of CNG with amino groups of proteins....

ea0063p145 | Diabetes, Obesity and Metabolism 1 | ECE2019

Retinol binding protein 4-marker insulin resistance in patients with diabetes mellitus 2 types and NAFLD

Larisa Zvenigorodskaya , Michael Shinkin , Tamara Nilova , Alexander Petrakov , Galina Varvanina

Introduction: Retinol binding protein (RSP) is a member of the adipokine family associated with insulin resistance (IR). With an excess of free fatty acids, the binding of insulin by hepatocyte receptors decreases and hyperinsulinemia develops. RSP is a transport protein for retinol, synthesized in hepatocytes and adipocytes. The level of RSP increased in patients with obesity, diabetes mellitus and non-alcoholic fatty liver disease (NAFLD) correlated positively with the sever...